Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Cohen, GB
Andrew Cohen, East Yorkshire GB
| Patent application number | Description | Published |
|---|---|---|
| 20090306785 | Knee joint prosthesis - A knee joint prosthesis which comprises a tibial component ( | 12-10-2009 |
Bernard Cohen, London GB
| Patent application number | Description | Published |
|---|---|---|
| 20100074911 | VACCINE NEBULIZERS - The invention provides a method of selecting or optimising a nebuliser device to be used to deliver a vaccine comprising selecting a nebuliser capable of producing a plurality of vaccine particles having the following particle droplet size distribution: | 03-25-2010 |
Emma Suzanne Cohen, Cambridge GB
| Patent application number | Description | Published |
|---|---|---|
| 20090130093 | BINDING MEMBER FOR GM-CSF RECEPTOR - Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFRα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis. | 05-21-2009 |
Gerald Cohen, Leicester GB
| Patent application number | Description | Published |
|---|---|---|
| 20090325867 | RECEPTOR-SPECIFIC TUMOUR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) VARIANTS - The invention relates to a tumour necrosis factor- (TNF-) related apoptosis-inducing ligand (TRAIL) which is capable of selectively signalling through death receptor 4 (DR4), comprising Y at position 189. Preferably the TRAIL further comprises 19 IL and/or 199V; preferably also 201R, 213W and 215D, and/or preferably further comprises 193S. The invention also relates to uses of such TRAIL mutants which are capable of selectively signalling through DR4 in the treatment of cancer, and in the manufacture of medicaments for use in treatment of cancer. Preferably the cancer is chronic lymphocytic leukaemia, mantle cell lymphoma or non-Hodgkin's lymphoma. The invention also relates to kits comprising same. | 12-31-2009 |
Grahame K. Cohen, London GB
| Patent application number | Description | Published |
|---|---|---|
| 20110107204 | AUTOMATED DOCUMENT ASSEMBLY WITH OBSCURING - A document assembly system includes a storage element ( | 05-05-2011 |
Grahame Keith Cohen, London GB
Mark B. Cohen, London GB
| Patent application number | Description | Published |
|---|---|---|
| 20090271704 | DISPLAYING HELP SENSITIVE AREAS OF A COMPUTER APPLICATION - A window of a computer application on a display device is controlled through associating a pop-up window with the screen window of the computer application, wherein the computer application provides more than one screen window and a pop-up window is associated with each screen window of the computer application, and at least one mouse-sensitive area is defined for each screen window of the computer application, such that a mouse click on a mouse-sensitive area causes the appropriate pop-up window to be displayed on the display device. | 10-29-2009 |
Patricia Townsend Wade Cohen, London GB
| Patent application number | Description | Published |
|---|---|---|
| 20100069502 | Assay - The invention relates to a method for identifying a candidate agent for use in a medicament for diabetes or obesity said method comprising (i) providing a candidate inhibitor of PPM phosphatase, (ii) providing a first and a second sample comprising PPM phosphatase, (iii) contacting said candidate inhibitor with said first sample comprising PPM phosphatase, and (iv) assaying said first and second samples for PPM phosphatase activity, wherein said PPM phosphatase is selected from the group consisting of PPM1E, PPM1F, PPM1J, PPM1K, PPM1L and PPM1M, wherein if the PPM phosphatase activity is lower in said first sample than in said second sample then said candidate inhibitor is identified as a candidate agent for use in a medicament for diabetes or obesity, preferably type II diabetes. The invention also relates to the use of metformin and phenformin as inhibitors of PPM phosphatases. | 03-18-2010 |
Philip Cohen, Invergowrie GB
| Patent application number | Description | Published |
|---|---|---|
| 20080213240 | RAC-PK as a therapeutic agent or in diagnostics, screening method for agents and process for activating RAC-PK - The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and/or excess blood sugar levels. Moreover, the invention provides RAC-PK for use in screening potential mimics or modulators thereof. A method for screening for agents capable of affecting the activity of GSK3 is also disclosed. The invention further provides a screening kit comprising the RAC-PK as an active principle, and a method for screening compounds which are candidate mimics or modulators of RAC-PK activity comprising detecting specific interactions between the candidate compounds and RAC-PK. There is also provided a process for activating RAC-PK comprising treatment thereof with a phosphatase inhibitor. | 09-04-2008 |
Philip Cohen, Dundee GB
| Patent application number | Description | Published |
|---|---|---|
| 20100063085 | METHOD OF TREATING LEARNING IMPAIRMENT IN DOWN'S SYNDROME SUBJECTS - The present invention provides compounds for use in the preparation of pharmaceutical formulations and medicaments, which alleviate learning and/or mental impairment in people suffering from Down's syndrome. | 03-11-2010 |
| 20100285124 | TETRAHYDROCYCLOPENTA[C]ACRIDINE DERIVATIVES AS KINASE INHIBITORS AND BIOLOGICAL - The invention relates to kinase inhibitors of the formula (I) in which —R | 11-11-2010 |
Richard Cohen, London GB
| Patent application number | Description | Published |
|---|---|---|
| 20090275965 | SURGICAL INSTRUMENT - A surgical device comprising a head with a cutting edge and a shaft is described for use in treating anal fistulas. The device facilitates the removal of tissue from the walls of the fistula allowing the introduction of collagen that aids the healing of the fistula. In this way a fistula may be closed without serious consequences to the continence of the patient. | 11-05-2009 |
Robert David Cohen, Edgeware GB
| Patent application number | Description | Published |
|---|---|---|
| 20100195658 | TELECOMMUNICATIONS SYSTEM - Virtual dedicated voice connections between parties to a packet-switched system can be created by reserving capacity for such connections in the packet-switched system. The capacity reservable by any one party is limited to prevent over-subscription of resources in the packet switched. The system incorporates a call admission control processor for controlling access to the packet-switched call routing system such that a voice call attempt is successful only if capacity for such a dedicated connection has previously been reserved. The capacity reserved for the virtual connections is made available for use by other traffic when not required for voice sessions. | 08-05-2010 |
Suzanne Cohen, Cambridge Cambridgeshire GB
| Patent application number | Description | Published |
|---|---|---|
| 20100150904 | BINDING MEMBERS FOR IGE MOLECULES - This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma. | 06-17-2010 |
Suzanne Cohen, Cambridge GB
| Patent application number | Description | Published |
|---|---|---|
| 20090060919 | BINDING MEMBERS FOR IgE MOLECULES - This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma. | 03-05-2009 |
| 20090202568 | Binding members for interleukin-4 receptor alpha (IL-4Ra)-173 - Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4Rα), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4Rα, IL-4 and/or IL-13, examples of which are asthma and COPD. | 08-13-2009 |
Suzanne E. Cohen, Hertfordshire GB
| Patent application number | Description | Published |
|---|---|---|
| 20100184960 | Antibodies Against Human IL-22 And Uses Therefor - The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders. | 07-22-2010 |
Zak Cohen, London GB
| Patent application number | Description | Published |
|---|---|---|
| 20110128288 | Region of Interest Selector for Visual Queries - A client system receives an image such as a photograph, a screen shot, a scanned image, or a video frame. The image has a first resolution which is likely larger than a maximum resolution for visual queries. As such, if a visual query were created from the image some resolution would be lost. Instead, a user selects a region of interest within the image. The region of interest has a second resolution, which is smaller than the first resolution. The client system then creates a visual query from the region of interest. The visual query has a resolution no larger than a pre-defined maximum resolution for visual queries. Because the visual query is created from the region of interest rather, than the entire received image, most of the resolution is concentrated specifically on the region of interest. The visual query is then sent to a server system. | 06-02-2011 |